OncoTargets and Therapy (Mar 2022)
Progression-Free Survival of a Patient with Advanced Hepatocellular Carcinoma Treated with Adoptive Cell Therapy Using Natural Killer Cells: A Case Report
Abstract
Guodai Hong,1 Silun Xie,2 Zikuan Guo,3 Diping Zhang,2 Sihai Ge,2 Suqin Zhang,1 Wenbin Gao1 1Department of Oncology, The Third Affiliated Hospital of Shenzhen University (Shenzhen Luohu People’s Hospital), Shenzhen, 518002, People’s Republic of China; 2Shenzhen Cell Biotechnology Co., Ltd, Shenzhen, 518054, People’s Republic of China; 3Beijing Clin- Biotechnology Co., Ltd, Beijing, 100070, People’s Republic of ChinaCorrespondence: Wenbin Gao, Department of Oncology, The Third Affiliated Hospital of Shenzhen University (Shenzhen Luohu People’s Hospital), Luohu District, Shenzhen, 518002, People’s Republic of China, Tel +86 132 6677 8968, Email [email protected]: Adoptive cell therapy (ACT) is a promising treatment that is considered safe and efficient. Natural killer (NK) cells play an important role in the innate immune system and destroy target cells such as tumor cells without prior sensitization. Here, we report a 59-year-old man with advanced diffuse hepatocellular carcinoma (HCC) who underwent 17 courses of NK cell treatment from March 2017 to July 2018. Although he presented with progressive disease, his hydrothorax and ascites decreased, and his state of mind, appetite and quality of life were markedly improved after treatment versus at admission. To date, his survival time is > 48 months. Here, we provide evidence that NK cell adoptive therapy has no adverse effects, enhances immune function, and improves the quality of life of patients with HCC.Keywords: hepatocellular carcinoma, natural killer cell therapy, prolonged survival
